Digestive Health Newsletter

The Scoop on the Scope - Prep Tips from a Pro

Lawrence B. Cohen, MD and Laura Strohmeyer, RN, CGRN

Volume 19, 
March 01, 2010

The Scoop on the Scope

by Lawrence B. Cohen, MD

Lawrence B. Cohen, MD Lawrence B. Cohen, MD, is an Associate Clinical Professor of Medicine and Associate Attending Physician at the Mount Sinai Medical Center and School of Medicine in New York City. In addition to his clinical positions, Dr. Cohen serves as Director of the Digestive Disease Research Foundation and the President of the Research Association of New York. He also actively participates in teaching activities at the Mount Sinai School of Medicine, serving five years as Director of the Gastrointestinal Pathophysiology course and twenty years as Director of the Gastrointestinal Motility Laboratory.



Table of Contents


Prep Tips from a Pro

by Laura Strohmeyer, RN, CGRN

Laura Strohmeyer, RN, CGRN Laura Strohmeyer, RN, CGRN, has facilitated support groups for patients with Crohn's disease and ulcerative colitis in the Dallas area for the past eight years. She has lectured regionally and nationally about inflammatory bowel disease (IBD) and the role of support groups for IBD patients. She has practiced as a gastroenterology nurse manager for over 25 years, and has been certified in gastroenterology nursing for the past 19 years. Laura is a former member of the Board of Trustees of the North Texas chapter of the Crohn's and Colitis Foundation of America. Since 2006, she has served on the Board of Directors for the Society of Gastroenterology Nurses and Associates. Ms. Strohmeyer is currently the Clinical Director for AmSurg and works with outpatient gastroenterology centers in Texas and Oklahoma.



Table of Contents

The Scoop on the Scope

Introduction

March is National Colorectal Cancer Awareness Month, and the best way to celebrate is to have a screening examination in order to reduce your risk of developing colon cancer.

Here are the stats:

  • Roughly one in 18 Americans will develop colorectal cancer during their lifetime.
  • There are about 150,000 new cases of colorectal cancer and almost 50,000 deaths from colorectal cancer in the U.S. each year.
  • Inflammatory bowel disease (IBD) increases your colorectal cancer risk by about two to five times the average risk.

But here is the good news:

If detected early, colorectal cancer is one of the most treatable cancers, and survival rates in people with IBD are the same as survival rates in the general population. What's even better is that screening can actually help prevent colorectal cancer.

When it comes to colorectal cancer screening, colonoscopy is the most comprehensive and reliable diagnostic tool. Colonoscopy allows your doctor to examine the lining of your colon by threading a colonoscope (a thin, flexible tube with a tiny video chip and light on the end) through the length of your colon. As the colonoscope is withdrawn, your doctor can examine the wall of your colon for polyps and other abnormalities, as well as remove or "biopsy" any abnormality that is found.

A successful colonoscopy depends on two key things:

  • how well you prepare for the procedure, and
  • how thoroughly your endoscopist examines the bowel wall during the procedure.

This newsletter will walk you through steps you can take to help ensure that your colonoscopy is as accurate as possible.

Back to Top

Preparation Quality

  • The importance of a clean colon

For an accurate colonoscopy, you must use a bowel cleansing product to completely empty your colon before the procedure. Thorough bowel cleansing makes it possible for your doctor to identify all colon polyps, as well as any other abnormality within your colon. It is important that the entire length of your colon is clean, so no sections are missed during your exam. A clean colon will decrease the chance of undiagnosed polyps and a need to return for a second exam. Click here to read "Prep Tips from a Pro" and learn how a gastroenterology nurse prepared for her first colonoscopy.

  • How do I know if my colon is completely cleaned out?

You can be confident that the bowel is adequately cleaned out if your rectal output is clear and contains no solid residue.

  • Following your doctor's instructions

When it comes to bowel preparation, it is critical to follow your doctor's instructions carefully and to complete the regimen exactly as prescribed. Pay close attention to the diet you are told to follow and any medication you are told to avoid prior to your procedure. Finally, because bowel preparation involves significant fluid loss, it is important to keep hydrated. Be sure to contact your doctor if you vomit or are unable to drink the amount of liquid prescribed.

  • Split dosing

New American College of Gastroenterology guidelines recommend "split dosing" or "PM/AM dosing." This simply means taking half of your bowel preparation regimen on the day before your colonoscopy and half on the day of your colonoscopy (i.e., within six hours of the procedure). For instance, if your colonoscopy is scheduled on Tuesday at 10:00 a.m., you would consume the first half of your bowel preparation regimen on Monday evening and start the second half on Tuesday at 4:00 a.m. Although there are a number of different bowel preparation products available, OsmoPrep® and MoviPrep® are the only two with FDA approval for split dosing1.

Split dosing may sound like a challenge, but research clearly indicates that it actually makes bowel preparation more tolerable. What's more, ten independent studies indicate that split dosing improves bowel preparation quality, especially on the right side of the colon. The right side of colon, or proximal colon, has traditionally been the most difficult to examine. It is also the area where abnormalities are most easily overlooked, since right–sided polyps tend to be flat and therefore easily obscured by small amounts of fluid or debris. When asked about bowel preparation in a recent study, more than 80% of patients said that they were willing to follow a split–dose regimen that involved getting up during the night, once they understood that doing so would help their doctor perform a more accurate examination.

Back to Top

Procedure Quality

A number of studies have shown that, in addition to bowel preparation quality, the ability to detect abnormal growths in the colon is also related to a variety of factors involving the colonoscopy procedure itself. These include the ability to reach the end of the colon, the time spent withdrawing the colonoscope, and the polyp detection rate. You can improve your odds of having a high quality colonoscopy by asking your doctor the following questions before scheduling your procedure. These questions are also summarized in an easy–to–use worksheet.

  • What is your training?

Your physician should be board certified in gastroenterology or colorectal surgery. Studies have shown that when internists and family practice physicians perform colonoscopies, they are less likely to detect cancer and precancerous growths.

  • How many colonoscopies do you do in a day?

Your physician should allow at least 30 minutes for each colonoscopy. Physicians performing more than 12–15 procedures a day may feel rushed and cut corners in order to stay on schedule.

  • How often are you able to insert the colonoscope the full length of the colon?

Your physician should reach the end of the colon (the cecum) during 90% or more of all procedures.

  • How long does it typically take you to withdraw the colonoscope?

Your physician should spend at least seven or eight minutes during withdrawal of the colonoscope to maximize the opportunity to inspect the bowel lining to detect cancer and precancerous growths. This is especially true when it comes to detecting flat polyps, which are often hidden in the colon wall and easily missed by withdrawing the colonoscope too quickly. In a recent study, doctors who took the most time during colonoscopy found more polyps than did doctors who took the least time.

  • How often do you identify and remove precancerous polyps during elective colonoscopy?

About 25% of men and 15–20% of women will have precancerous polyps during their first screening exam, so your doctor's detection rate should be at least that high.

Back to Top

Conclusion

Scheduling a colonoscopy probably isn't on your list of favorite things to do, but it can save your life. So if you're due (or overdue) for routine screening, take care of it this month. By using the tips presented in this newsletter, you can take steps toward getting the maximum benefit from the procedure. Remember that, although no diagnostic test is perfect, colonoscopy is considered to be the best method for detecting colorectal cancer while it can still be successfully treated.



Back to Top

Prep Tips from a Pro

They say nurses are the worse patients. As a nurse who has worked in GI Endoscopy for over 26 years I know the importance of a colonoscopy for colon cancer screening. There is nothing more devastating than seeing a patient diagnosed with colon cancer that did not have a screening colonoscopy as recommended. I have assisted with thousands of colonoscopies over the years, and hear the patients rejoice when it is over. But they all seem to say the same thing, "This was a piece of cake, the prep was the worst part!"

As I turned 50 almost 2 years ago, so many things went through my mind. It is a time to reflect on what I have accomplished in my life, and what lies ahead. As I was blowing out the black candles on my ‘over–the–hill' birthday cake, the reality hit me that it was now my turn to have a colonoscopy. I used every excuse in the book to postpone it, and taking the time out of my busy schedule for the procedure was next to impossible. I lectured my co–worker Teresa on her birthday for not having a colonoscopy, and admitted that I was just as guilty. That day we scheduled our colonoscopies together. My own health was not reason enough to be screened– it wasn't until I felt I needed to do it to motivate someone else. How typical for a nurse!

Knowing the variety of different preps available, I suggested that we take a ‘pill' prep1. I liked the idea of drinking different juices and beverages of my choosing, instead of a huge jug of liquid prep solution. I also knew that we needed to drink additional liquids prior to, during, and after the prep to keep from getting dehydrated. I went to the grocery store and bought about six different kinds of drinks, everything from apple juice, lemonade, pear– flavored water, and Gatorade. At work the day before our procedure, we shared broth, jello, and juices galore. We left work early to go home and start the colon prep. We were well prepared. We had hemorrhoid wipes, air freshener, and Teresa even had a TV tray set up with her laptop in the bathroom. We started communicating through our BlackBerry devices, and started our preps at exactly the same time. It was a unique experience having a ‘prep–pal'. We both experienced the same things at the same time, and we took every opportunity to make it a humorous experience. There were comments back and forth for the next five hours, until Teresa finally wrote, "I'm going to bed now, I'm pooped!"

The prep experience was much better than I expected. I think it helped being prepared and stocking up on a wide variety of liquids. I was never hungry and the prep started to work gradually so I never had any cramping. After a couple hours we both experienced chills from all the cold fluids. I just bundled up and got in bed to watch TV. I came up with a new invention, a Prep–Snuggy, they are open in the back aren't they?

As my patients have told me, the rest was a breeze. I was well sedated during the procedure and woke to find that I had three polyps removed, polyps that someday could have grown into cancer. A colonoscopy not only detects cancer, it prevents it. Why would anyone put this off?

Because I work with outpatient endoscopy centers, I have incorporated my colonoscopy experience at work. I am even more passionate about colon cancer screening and Teresa and I both signed up for the local Undy 5000, a national event where walkers wear their underwear to raise awareness for colon cancer screening. I am fortunate to use this experience to educate and encourage others to get screened. Maybe I'm not such a bad patient after all.



References

  1. See below for Important Safety Information about OsmoPrep

Back to Top

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter